X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
ADLARITY (donepezil transdermal system) developed by Corium, is the first and only U.S. FDA approved once-weekly, donepezil transdermal system for patients with mild, moderate and severe dementia of the Alzheimer's type.
Lead Product(s): Donepezil
Therapeutic Area: Neurology Product Name: Adlarity
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
Under the terms of the agreement, Lotus will have exclusive rights to commercialize Adlarity (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in the applicable territory and will be responsible for the regulatory approval process.
Lead Product(s): Donepezil
Therapeutic Area: Neurology Product Name: Adlarity
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lotus Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 10, 2023
Details:
SUVN-502 (masupirdine) is a novel, potent, pure, and orally active 5-HT6 receptor antagonist, it is being investigated as a potential therapy against alzheimer's disease.
Lead Product(s): Masupirdine,Donepezil,Memantine Hydrochloride
Therapeutic Area: Neurology Product Name: SUVN-502
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2023
Details:
Cognic (donepezil) is a transactive response DNA binding protein of 43 kDa (TDP-43) is involved in regulation of gene expression. AD patients with TDP-43 pathology have increased severity of cognitive impairment compared to those without TDP-43 pathology.
Lead Product(s): Donepezil,Memantine Hydrochloride
Therapeutic Area: Neurology Product Name: Cognic
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
The results of Study 419 did not show statistically significant difference in efficacy between placebo and Aricept (donepezil hydrochloride) groups at time of final analysis in primary endpoint, CIBIC-plus comprehensive assessment.
Lead Product(s): Donepezil
Therapeutic Area: Neurology Product Name: Aricept
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
ADLARITY is the first and only once-weekly patch to continuously deliver consistent doses of donepezil through the skin. Donepezil is the most prescribed medication in a class of Alzheimer's drugs known as acetylcholinesterase inhibitors.
Lead Product(s): Donepezil
Therapeutic Area: Neurology Product Name: Adlarity
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2022
Details:
KemPharm is due to receive the fee, within 30 days following FDA approval of ADLARITY, pursuant to a master development services agreement entered into with Corium in July 2020, under which KemPharm provided development related to Corium’s resubmission of its NDA for ADLARITY.
Lead Product(s): Donepezil
Therapeutic Area: Neurology Product Name: Adlarity
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Corium
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Agreement March 16, 2022
Details:
The approval of ADLARITY (donepezil transdermal system) reinforces the value of Corium's innovative CORPLEX technology, our CNS expertise, and our mission to deliver solutions that transform care for the Alzheimer's community and others impacted by CNS diseases.
Lead Product(s): Donepezil
Therapeutic Area: Neurology Product Name: Adlarity
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2022
Details:
Donepezil is a current typical treatment that has been widely prescribed for the longest period for Alzheimer’s disease patients in severity ranging from mild to moderate and severe ones among FDA-approved Alzheimer's treatments.
Lead Product(s): Donepezil
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2021
Details:
The ADLARITY transdermal patch is constructed to be worn for seven days with consistent adhesion, a delivery method that avoids the difficulties associated with daily delivery of an oral medication for patients with significant memory problems.
Lead Product(s): Donepezil
Therapeutic Area: Neurology Product Name: Adlarity
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2021
Details:
SUVN-502 (Masupirdine), a lead clinical candidate having undergone phase 2 study on 564 patients for moderate Alzheimer’s disease without meeting primary end point.
Lead Product(s): Masupirdine,Donepezil,Memantine Hydrochloride
Therapeutic Area: Neurology Product Name: SUVN-502
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2021
Details:
THN201 significantly increased EEG power in the gamma band related to cognitive activity. Similar profile with respect to other pharmacological, pharmacokinetic and tolerance endpoints was observed.
Lead Product(s): Donepezil,Mefloquine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
